Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaboration arrangement

Net revenue recognized under our GSK Agreement was as follows:


		Three Months Ended June 30,								Six Months Ended June 30,
(In thousands)		2026				2025				2026				2025
Royalties - RELVAR®/BREO®		$	47,655			$	54,737			$	94,931			$	105,627
Royalties - ANORO®			12,135				12,599				23,482				22,972
Total royalties			59,790				67,336				118,413				128,599
Less: amortization of capitalized fees paid			(3,456	)			(3,456	)			(6,912	)			(6,912	)
Total royalty revenue		$	56,334			$	63,880			$	111,501			$	121,687

Schedule of net product sales

Total net product sales were as follows:


		Three Months Ended June 30,								Six Months Ended June 30,
(In thousands)		2026				2025				2026				2025
GIAPREZA®		$	22,299			$	17,329			$	42,530			$	35,602
XACDURO®			22,382				10,731				40,456				18,514
XERAVA®			6,739				7,094				9,367				11,317
ZEVTERA®			351				339				789				339
Total net product sales		$	51,771			$	35,493			$	93,142			$	65,772